Develops and commercializes treatments for rare endocrine diseases and oncology, focusing on innovative therapeutic approaches.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapeutics and diagnostic tests. At the forefront of its portfolio is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist. This lead product stimulates the secretion of growth hormone by binding to GHSR-1a, serving as a diagnostic tool for adult growth hormone deficiency, childhood-onset growth hormone deficiency, and various oncology indications. Marketed under the Macrilen brand name, macimorelin exemplifies Aeterna Zentaris' commitment to advancing treatments that address critical medical needs.
In collaboration with University Wuerzburg, Aeterna Zentaris is actively engaged in research, development, and potential commercialization of a COVID-19 vaccine. Additionally, the company's partnership focuses on the development and commercialization of treatments for neuromyelitis optica spectrum disorder, as well as human 3D intestinal tissue models to study infection biology. Aeterna Zentaris also collaborates with various entities, including Consilient Health Ltd., Novo Nordisk Health Care AG, NK MEDITECH Ltd., and The University of Sheffield, for the development and commercialization of macimorelin and parathyroid hormone fusion polypeptides, further expanding its therapeutic reach in North America and globally.
Founded in 1990 and headquartered in Summerville, South Carolina, Aeterna Zentaris continues to pioneer advancements in biopharmaceuticals. With a robust pipeline and strategic partnerships, the company is poised to make significant strides in healthcare innovation, aiming to improve patient outcomes across a spectrum of diseases and conditions.